JP2018533591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533591A5 JP2018533591A5 JP2018523451A JP2018523451A JP2018533591A5 JP 2018533591 A5 JP2018533591 A5 JP 2018533591A5 JP 2018523451 A JP2018523451 A JP 2018523451A JP 2018523451 A JP2018523451 A JP 2018523451A JP 2018533591 A5 JP2018533591 A5 JP 2018533591A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- siglec15
- modulator
- item
- siglec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000709472 Homo sapiens Sialic acid-binding Ig-like lectin 15 Proteins 0.000 claims description 130
- 102100034361 Sialic acid-binding Ig-like lectin 15 Human genes 0.000 claims description 130
- 238000000034 method Methods 0.000 claims description 96
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 claims description 53
- 101000619621 Homo sapiens Leucine-rich repeat-containing protein 4C Proteins 0.000 claims description 53
- 101000616778 Homo sapiens Myelin-associated glycoprotein Proteins 0.000 claims description 53
- 102100022187 Leucine-rich repeat-containing protein 4C Human genes 0.000 claims description 53
- 102100021831 Myelin-associated glycoprotein Human genes 0.000 claims description 53
- 230000000694 effects Effects 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 36
- 150000007523 nucleic acids Chemical class 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 108020001507 fusion proteins Proteins 0.000 claims description 26
- 102000037865 fusion proteins Human genes 0.000 claims description 26
- 150000003384 small molecules Chemical class 0.000 claims description 26
- 208000023275 Autoimmune disease Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 20
- 230000028709 inflammatory response Effects 0.000 claims description 20
- 239000003112 inhibitor Substances 0.000 claims description 19
- 230000001603 reducing effect Effects 0.000 claims description 19
- 210000004556 brain Anatomy 0.000 claims description 18
- 239000005557 antagonist Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 239000012190 activator Substances 0.000 claims description 13
- 230000008685 targeting Effects 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 12
- RMINQIRDFIBNLE-NNRWGFCXSA-N O-[N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosaminyl]-L-serine Chemical compound O1[C@H](OC[C@H](N)C(O)=O)[C@H](NC(=O)C)[C@@H](O)[C@@H](O)[C@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 RMINQIRDFIBNLE-NNRWGFCXSA-N 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 238000013518 transcription Methods 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 10
- 238000013519 translation Methods 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims description 5
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 3
- -1 is the modulator Proteins 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021121460A JP2021167353A (ja) | 2015-11-10 | 2021-07-26 | 自己免疫疾患およびがんを処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562253437P | 2015-11-10 | 2015-11-10 | |
| US62/253,437 | 2015-11-10 | ||
| PCT/US2016/061086 WO2017083354A1 (en) | 2015-11-10 | 2016-11-09 | Compositions and methods for treating autoimmune diseases and cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121460A Division JP2021167353A (ja) | 2015-11-10 | 2021-07-26 | 自己免疫疾患およびがんを処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533591A JP2018533591A (ja) | 2018-11-15 |
| JP2018533591A5 true JP2018533591A5 (enExample) | 2019-12-05 |
| JP6924495B2 JP6924495B2 (ja) | 2021-08-25 |
Family
ID=58695157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018523451A Active JP6924495B2 (ja) | 2015-11-10 | 2016-11-09 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2021121460A Pending JP2021167353A (ja) | 2015-11-10 | 2021-07-26 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2023081549A Pending JP2023096078A (ja) | 2015-11-10 | 2023-05-17 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2025129444A Pending JP2025156500A (ja) | 2015-11-10 | 2025-08-01 | 自己免疫疾患およびがんを処置するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121460A Pending JP2021167353A (ja) | 2015-11-10 | 2021-07-26 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2023081549A Pending JP2023096078A (ja) | 2015-11-10 | 2023-05-17 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2025129444A Pending JP2025156500A (ja) | 2015-11-10 | 2025-08-01 | 自己免疫疾患およびがんを処置するための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180318419A1 (enExample) |
| EP (2) | EP4512827A3 (enExample) |
| JP (4) | JP6924495B2 (enExample) |
| KR (1) | KR102810368B1 (enExample) |
| CN (2) | CN116510015A (enExample) |
| AU (2) | AU2016354100B2 (enExample) |
| BR (1) | BR112018009361A8 (enExample) |
| CA (1) | CA3002095A1 (enExample) |
| HK (1) | HK1259294A1 (enExample) |
| MX (2) | MX2018005830A (enExample) |
| RU (1) | RU2761980C2 (enExample) |
| TW (2) | TW202330019A (enExample) |
| WO (1) | WO2017083354A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JP7069177B2 (ja) | 2016-09-21 | 2022-05-17 | ネクストキュア インコーポレイテッド | シグレック－１５に対する抗体及びその使用方法 |
| CN113138273B (zh) * | 2020-01-17 | 2024-06-18 | 孟民杰 | 一种应用于肺癌快速筛查及免疫靶向治疗检测的试剂盒及其用途 |
| JP7364315B2 (ja) * | 2020-03-27 | 2023-10-18 | ビオシオン インコーポレイテッド | 抗体結合Ｓｉｇｌｅｃ１５及びその使用 |
| CN113817057B (zh) * | 2020-06-19 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗siglec15抗体及其应用 |
| CN114525256A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用 |
| CA3204359A1 (en) * | 2020-12-08 | 2022-06-16 | Guizhou Sinorda Biotechnology Co. Ltd. | Modified t cells for adoptive immunotherapy |
| CN114657132A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Siglec-15靶向抑制因子的多能干细胞及其衍生物与应用 |
| ES2955819T3 (es) * | 2021-01-21 | 2023-12-07 | Guizhou Sinorda Biotechnology Co Ltd | Linfocitos T modificados para inmunoterapia adoptiva |
| EP4299591A4 (en) * | 2021-02-23 | 2025-03-12 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | Production of Siglec-15 binding protein and use thereof |
| CN114957468A (zh) * | 2021-02-25 | 2022-08-30 | 石药集团巨石生物制药有限公司 | 一种抗Siglec15抗体及其用途 |
| WO2022188871A1 (en) * | 2021-03-12 | 2022-09-15 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric siglec15 |
| CN116983412A (zh) * | 2023-08-04 | 2023-11-03 | 南通大学 | Siglec-15-SE超增强子在制备治疗肿瘤的产品中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
| US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| AU731044B2 (en) * | 1995-06-27 | 2001-03-22 | Research Foundation Of Cuny, Hunter College | Compositions and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof |
| IL162077A0 (en) * | 2001-11-21 | 2005-11-20 | Univ Leland Stanford Junior | Polynucleotide therapy the board of trustees of the leland stanford junior university |
| GB0509438D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| EP2056865B1 (en) * | 2006-08-28 | 2013-12-25 | Omnio Healer AB | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| EP2907826B1 (en) * | 2007-10-11 | 2018-05-30 | Daiichi Sankyo Company, Limited | Antibody targeting osteoclast-related protein siglec-15 |
| US8575316B2 (en) | 2009-04-09 | 2013-11-05 | Daiichi Sankyo Company, Limited | Anti-Siglec-15 antibody |
| GEP201706660B (en) * | 2010-03-04 | 2017-04-25 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| CN103328005A (zh) * | 2010-08-13 | 2013-09-25 | 贝勒研究院 | 基于将到抗体的佐剂直接靶向抗原呈递细胞的新型疫苗佐剂 |
| US9114131B2 (en) * | 2010-10-05 | 2015-08-25 | Daiichi Sankyo Company, Limited | Antibody targeting osteoclast-related protein Siglec-15 |
| US20150299255A1 (en) * | 2010-11-01 | 2015-10-22 | Susavion Biosciences, Inc. | Compositions and methods for modulating innate and adaptive immune systems |
| EP2753356B1 (en) * | 2011-09-09 | 2021-12-22 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
| EP2610263A1 (de) * | 2011-12-30 | 2013-07-03 | Brossmer, Reinhard | Sialinsäure-Dimere |
| US20160264684A1 (en) * | 2013-10-10 | 2016-09-15 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MX384991B (es) * | 2014-03-19 | 2025-03-14 | Genzyme Corp | Glucomodificación de restos de direccionamiento específica del sitio. |
-
2016
- 2016-11-09 CN CN202310352979.8A patent/CN116510015A/zh active Pending
- 2016-11-09 EP EP24202238.2A patent/EP4512827A3/en active Pending
- 2016-11-09 MX MX2018005830A patent/MX2018005830A/es unknown
- 2016-11-09 TW TW112112070A patent/TW202330019A/zh unknown
- 2016-11-09 CN CN201680065576.3A patent/CN108430498A/zh active Pending
- 2016-11-09 EP EP16864893.9A patent/EP3373962A4/en not_active Withdrawn
- 2016-11-09 TW TW105136406A patent/TWI847955B/zh active
- 2016-11-09 US US15/775,084 patent/US20180318419A1/en not_active Abandoned
- 2016-11-09 HK HK19101657.1A patent/HK1259294A1/zh unknown
- 2016-11-09 BR BR112018009361A patent/BR112018009361A8/pt not_active Application Discontinuation
- 2016-11-09 KR KR1020187015768A patent/KR102810368B1/ko active Active
- 2016-11-09 JP JP2018523451A patent/JP6924495B2/ja active Active
- 2016-11-09 WO PCT/US2016/061086 patent/WO2017083354A1/en not_active Ceased
- 2016-11-09 CA CA3002095A patent/CA3002095A1/en active Pending
- 2016-11-09 RU RU2018121050A patent/RU2761980C2/ru active
- 2016-11-09 AU AU2016354100A patent/AU2016354100B2/en active Active
-
2018
- 2018-05-09 MX MX2023012451A patent/MX2023012451A/es unknown
-
2021
- 2021-07-26 JP JP2021121460A patent/JP2021167353A/ja active Pending
-
2022
- 2022-02-16 US US17/673,034 patent/US20220168419A1/en active Pending
-
2023
- 2023-05-17 JP JP2023081549A patent/JP2023096078A/ja active Pending
-
2024
- 2024-02-27 AU AU2024201282A patent/AU2024201282A1/en active Pending
-
2025
- 2025-08-01 JP JP2025129444A patent/JP2025156500A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533591A5 (enExample) | ||
| Haanen et al. | Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy | |
| Hatakeyama et al. | ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments | |
| Liu et al. | Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy | |
| Maddison et al. | Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome | |
| RU2018121050A (ru) | Композиции и способы лечения аутоиммунных заболеваний и рака | |
| Johnson et al. | Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma | |
| Doebele et al. | Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer | |
| PH12019500270A1 (en) | Combination therapy for cancer | |
| Fujita et al. | C‐reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib | |
| Wu et al. | Molecular basis of therapeutic approaches to gastric cancer | |
| Henriques et al. | Toll-like receptor-4 disruption suppresses adipose tissue remodeling and increases survival in cancer cachexia syndrome | |
| Yu et al. | Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma | |
| MA41038A (fr) | Composés d'aminopyridyloxypyrazole | |
| He et al. | Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer | |
| PH12018502046A1 (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| PH12022550122A1 (en) | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer | |
| Qu et al. | Loss of CD 155 expression predicts poor prognosis in hepatocellular carcinoma | |
| Ascierto et al. | Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? | |
| Wang et al. | Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer | |
| MX385589B (es) | RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM. | |
| Zhu et al. | FBI-1 enhances ETS-1 signaling activity and promotes proliferation of human colorectal carcinoma cells | |
| Matsuoka et al. | Bevacizumab exacerbates paclitaxel-induced neuropathy: a retrospective cohort study | |
| JOP20220057A1 (ar) | علاج أمراض أو اضطرابات الكبد تشتمل على مضادات مستقبل actrii | |
| Finkelmeier et al. | Bevacizumab in combination with chemotherapy for colorectal brain metastasis |